Nasdaq GlobeNewswire

Oxford Immunotec Reports Second Quarter 2017 Financial Results

  • Second quarter revenue of $26.1 million, an increase of 36% compared to prior year period
  • Continued growth from both the Tuberculosis and Tick-borne disease franchises
  • Successful negotiation of a settlement with Statens Serum Institut which will result in substantial future gross margin improvement
  • Raising revenue guidance for the full year from $102-$105 million to $103-$106 million

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced second quarter 2017 financial results.

"We delivered a strong second quarter with revenue growth that exceeded the top end of our guidance range," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "As we continue our evolution from a single-product company to a multi-product company, we are pleased to see solid growth in our core tuberculosis (TB) business as well as a strong contribution from our accelerating tick-borne disease franchise."

By revenue type, total revenues were, in millions:

    Three Months Ended June 30,  
      2017     2016   Percent 

Product   $ 10.4   $ 9.3   12 %  
Service     15.7     9.9   59 %  
Total Revenue   $   26.1   $   19.2   36 %  

By indication, total revenues were, in millions:

    Three Months Ended June 30,  
      2017     2016   Percent 

Tuberculosis   $ 21.3   $ 19.2   12 %  
Tick-Borne Disease and Other     4.8     -   NM    
Total Revenue   $    26.1   $   19.2     36 %  

By geography, total revenues were, in millions:

    Three Months Ended June 30,  
            Percent Change  
      2017     2016   As Reported   Constant 
United States   $ 16.1   $ 9.8   65 %   65 %  
Europe & ROW     1.9     2.0   -2 %   3 %  
Asia     8.1     7.4   9 %   8 %  
Total revenue   $   26.1   $   19.2   36 %   36 %

(1) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

Settlement with Statens Serum Institut

During the quarter, we reached a settlement over a dispute regarding our license agreement with Statens Serum Institut (SSI). The terms of the settlement are confidential, however, we expect this settlement to result in a 300-400 basis point improvement in future TB gross margins.

Second Quarter 2017 Financial Results

Revenue for the second quarter of 2017 was $26.1 million, representing 36% growth over second quarter 2016 revenue of $19.2 million. On a constant currency basis, revenue growth was also 36% versus the prior year period. Tuberculosis revenue for the second quarter of $21.3 million increased 12% over the prior year period. 

2017 second quarter product revenue was $10.4 million, representing a 12% increase from product revenue of $9.3 million in the second quarter of 2016. The increase was primarily driven by sales of tick-borne disease kits as well as growth in Asia. Service revenue for the second quarter of 2017 was $15.7 million, up 59% from 2016 second quarter revenue of $9.9 million. The increase in service revenue was primarily driven by tuberculosis volume increases in the United States as well as revenues from our tick-borne disease testing business.

United States revenue was $16.1 million in the second quarter of 2017, representing 65% growth over revenue of $9.8 million in the prior year period. The increase was due to growth in our core tuberculosis business as well as the additional contribution from our tick-borne disease business.

Europe & ROW revenue was $1.9 million in the second quarter of 2017, representing a 2% decrease compared to the second quarter of 2016. On a constant currency basis, Europe & ROW increased 3% versus the second quarter of 2016. The increase was primarily due to TB growth, particularly in the UK, and sales of tick-borne disease kits.

Asia revenue was $8.1 million in the second quarter of 2017, representing an increase of 9% over 2016 second quarter revenue of $7.4 million. On a constant currency basis, Asia increased 8% versus the second quarter of 2016. The increase was due to the timing of orders in China and increasing sales in South Korea.

Gross profit for the second quarter of 2017 was $13.6 million, an increase of $3.1 million over gross profit of $10.5 million in the same period of 2016. Gross margin was 52.2%, a decrease of 290 basis points from the gross margin of 55.1% in the second quarter of 2016. The second quarter gross margin performance reflects an underlying improvement in TB margins offset by the addition of our tick-borne disease businesses, which carry lower gross margins.

Operating expenses were $31.4 million in the second quarter of 2017, an increase of $13.5 million compared to $17.9 million in the same period last year. The increase in operating expenses was largely due to the inclusion of a one-time charge related to the SSI settlement as well as expenses related to our BLA submissions and ongoing patent litigation.

Net loss for the second quarter of 2017 was $16.8 million, or $0.74 per share, compared to $6.4 million, or $0.29 per share, in the second quarter of 2016. Net loss per share was based on 22,805,379 and 22,351,645 weighted average ordinary shares outstanding for the second quarters of 2017 and 2016, respectively. 

EBITDA for the second quarter was $(17.4) million compared to $(5.8) million in the second quarter of 2016. Adjusted EBITDA was $(6.3) million for the second quarter compared to $(5.3) million in the same period in 2016. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Business Outlook

We expect to report revenue of between $29.5 and $30.5 million for the third quarter of 2017.

We now expect to report full year 2017 revenue of between $103 and $106 million, representing 20% - 23% year-over-year growth. We expect revenue to increase approximately 21% to 24% for the year using constant exchange rates. This compares to prior revenue guidance of between $102 and $105 million.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, August 1, 2017 at 8:00 a.m. Eastern Time to discuss its second quarter 2017 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 54321779 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics.  Also obtained through the acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure.  The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company's fourth intended product line focused on the transplantation market.  In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions.  The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, intentions, the anticipated benefits of the transaction, the effects of the transaction, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: risks related to disruption of management time from ongoing business operations due to the integration of Imugen and Immunetics into the Company; the risk that the Company may fail to realize the benefits expected from the acquisitions; the risk that the integration of Imugen and Immunetics into the Company may not progress as anticipated; decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website,, or the SEC's website,

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.


For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501

Oxford Immunotec Global PLC
Condensed consolidated statements of operations
    Three months ended June 30,   Six months ended June 30,
(in thousands, except share and per share data)     2017       2016       2017       2016  
Product   $ 10,422     $ 9,293     $ 18,808     $ 17,431  
Service     15,698       9,861       28,817       18,833  
Total revenue     26,120       19,154       47,625       36,264  
Cost of revenue                
Product     4,094       3,512       7,339       6,805  
Service     8,398       5,094       15,650       9,966  
Total cost of revenue     12,492       8,606       22,989       16,771  
Gross profit     13,628       10,548       24,636       19,493  
Operating expenses:                
Research and development     3,948       3,284       7,753       6,305  
Sales and marketing     10,041       9,391       19,681       17,871  
General and administrative     7,990       5,151       14,866       9,734  
Change in fair value of contingent purchase price consideration     (238 )     57       (2,595 )     112  
Settlement expense     9,635       -       9,635       -  
Total operating expenses     31,376       17,883       49,340       34,022  
Loss from operations     (17,748 )     (7,335 )     (24,704 )     (14,529 )
Other income (expense):                
Interest expense, net     (807 )     (17 )     (1,630 )     (34 )
Foreign exchange (losses) gains     (547 )     874       (653 )     1,237  
Other (expense) income     (122 )     29       (262 )     (137 )
Loss before income taxes     (19,224 )     (6,449 )     (27,249 )     (13,463 )
Income tax benefit (expense)     2,458       3       2,411       (32 )
Net loss   $ (16,766 )   $ (6,446 )   $ (24,838 )   $ (13,495 )
Net loss per share attributable to ordinary shareholders-basic and diluted   $ (0.74 )   $ (0.29 )   $ (1.10 )   $ (0.60 )
Weighted-average shares used to compute net loss attributable to ordinary shareholders-basic and diluted     22,805,379       22,351,645       22,670,206       22,318,019  

Reconciliation of net loss to Adjusted EBITDA (1)
    Three months ended June 30,   Six months ended June 30,
(in thousands)     2017       2016       2017       2016  
Net loss   $ (16,766 )   $ (6,446 )   $ (24,838 )   $ (13,495 )
Income tax expense (benefit)     (2,458 )     (3 )     (2,411 )     32  
Interest expense, net     667       17       1,341       34  
Depreciation and amortization of intangible assets     990       624       1,993       1,205  
Accretion and amortization of loan fees     140       -       289       -  
EBITDA     (17,427 )     (5,808 )     (23,626 )     (12,224 )
Reconciling items:                
Share-based compensation expense     1,434       1,355       2,760       2,459  
Unrealized exchange losses (gains)     319       (896 )     281       (1,418 )
Change in fair value of contingent purchase price consideration     (238 )     57       (2,595 )     112  
Settlement expense     9,635       -       9,635       -  
Adjusted EBITDA   $ (6,277 )   $ (5,292 )   $ (13,545 )   $ (11,071

EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
    June 30,   December 31,
(in thousands, except share and per share data)     2017       2016  
Current assets:        
Cash and cash equivalents   $ 36,713     $ 59,110  
Accounts receivable, net     18,016       13,265  
Inventory, net     9,480       7,437  
Prepaid expenses and other assets     2,907       2,390  
Total current assets     67,116       82,202  
Restricted cash, non-current     200       200  
Property and equipment, net     8,786       7,793  
In-process research and development     16,170       16,170  
Goodwill     3,967       3,822  
Other intangible assets, net     10,410       11,017  
Deferred tax asset     6,133       2,630  
Other assets     145       178  
Total assets   $ 112,927     $ 124,012  
Liabilities and shareholders' equity        
Current liabilities:        
Accounts payable   $ 3,874     $ 3,201  
Accrued liabilities     15,734       14,282  
Settlement liability     2,317       -  
Contingent purchase price consideration     880       882  
Deferred income     43       41  
Current portion of loans payable     87       84  
Total current liabilities     22,935       18,490  
Long-term portion of loans payable     29,670       29,601  
Settlement liability     7,472       -  
Contingent purchase price consideration     -       2,593  
Other liabilities     364       364  
Total liabilities     60,441       51,048  
Shareholders' equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at June 30, 2017 and 
December 31, 2016, and 23,014,032 and 22,635,431 shares issued and outstanding at June 
30, 2017 and December 31, 2016, respectively
    247       243  
Additional paid-in capital     251,989       249,128  
Accumulated deficit     (193,494 )     (168,656 )
Accumulated other comprehensive loss     (6,256 )     (7,751 )
Total shareholders' equity     52,486       72,964  
Total liabilities and shareholders' equity   $ 112,927     $ 124,012  

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Cisco 2018 Annual Cybersecurity Report Reveals Security Leaders Rely on and Invest in Automation, Machine Learning and Artificial Intelligence to Defend Against Threats21.2.2018 14:00Pressemelding

Findings show 39 percent of organizations are reliant on automation, 34 percent are reliant on machine learning, 32 percent are highly reliant on AI SAN JOSE, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Malware sophistication is increasing as adversaries begin to weaponize cloud services and evade detection through encryption, used as a tool to conceal command-and-control activity. To reduce adversaries' time to operate, security professionals said they will increasingly leverage and spend more on tools that use AI and machine learning, reported in the 11th Cisco® 2018 Annual Cybersecurity Report (ACR). While encryption is meant to enhance security, the expanded volume of encrypted web traffic (50 percent as of October 2017) - both legitimate and malicious - has created more challenges for defenders trying to identify and monitor potential threats. Cisco threat researchers observed more than a threefold increase in encrypted network communication used by inspected malware samples over a

Appian Corporation : Banco Santander Selects Appian21.2.2018 13:30Pressemelding

RESTON, Va., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN), a leading low-code and business process management platform provider, today announced that it has signed a global agreement with Banco Santander (SAN SM, STD US, BNC LN). Banco Santander, the largest bank in the Eurozone by market capitalization, will leverage Appian's platform in the cloud for enterprise process improvement. Banco Santander is a leader in retail and commercial banking, and has a meaningful market share in 10 core countries in Europe and the Americas. Appian has been chosen because it provides a comprehensive platform for Business Process Management (BPM) and Case Management in a digital environment, and the ability to deploy applications through fast and simple low-code development. Appian Cloud has an extensive collection of security accreditations, making it a highly trusted platform for rapid application development. Appian is accredited for HIPAA, SOC 2 and SOC 3, The PCI Data Security Standard,

Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call21.2.2018 13:00Pressemelding

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2017 financial results will be released on Thursday, March 1, 2018 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, March 1, 2018, at 4:30 p.m. Eastern Time to discuss the financial results and its plans for addressing the Vitaros Complete Response with the FDA. To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 3687726. The live audio webcast can be accessed via the Investor Relations' section of the Company's website at Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call. About Apricus Biosciences, Inc

Purepoint Uranium Acquires Strategic Land Positions in the Athabasca Basin, Saskatchewan21.2.2018 12:45Pressemelding

TORONTO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (the "Company" or "Purepoint") (TSX.V:PTU) today reported that since October, 2017 it has acquired through staking an additional 52,479 hectares of mineral claims in the Athabasca Basin, Saskatchewan Canada representing a substantial increase in the Company's 100% owned projects. "We have taken a very precise and strategic approach to our staking - focusing on the enlargement of our existing projects or securing highly prospective areas of defined potential," said Chris Frostad, President & CEO at Purepoint. "Over the past four months we have successfully added three new projects, enlarged two existing projects and nearly doubled our 100% owned land position". "Much of our new ground lies on the SW edge of the Athabasca Basin, proximal to our Smart Lake Project. Our initial drilling at Smart Lake identified a radioactive shear that was associated with intense alteration," said Scott Frostad, Vice President Explorat

Aurora Releases Third Quarter Results20.2.2018 21:08Pressemelding

Aurora Solar Technologies Inc. / Aurora Releases Third Quarter Results . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. NORTH VANCOUVER, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora")("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82), a leader in inline measurement and control technology for the photovoltaic manufacturing industry, released today its third quarter results. Revenue for the quarter was $337,325, gross margin was 62.9%, resulting in an operating income loss of ($398,959). Year-to-date for nine months, the Company has recognized $1,903,020 in revenue, an increase of 238% over the same period last year. The operating income (loss) year to date was ($674,983), a reduction of 67.7% from the same period last fiscal year. The Company also confirms, excluding new potential orders, that it has unrecognized revenue from shipments and order backlog of approxi

Bermuda Principles event merges science and business20.2.2018 16:36Pressemelding

HAMILTON, Bermuda, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Scientists and researchers from around the world are gathering in Bermuda this week for the second edition of a conference exploring the field of genetic research. Premier the Hon David Burt will officially open "Bermuda Principles: Impact on Splicing" Wednesday evening at the Fairmont Southampton. The conference, which runs through Saturday, has registered 50 delegates, along with an impressive roster of 36 speakers and panellists from 11 countries, including Australia, Denmark, Switzerland and South Africa. Among the attendees are prominent geneticists, scientists, professors, researchers, PhD students working in international labs, biotech representatives and investors. "I am elated to see the growth of the conference since last year's event," said Bermudian Dr. Carika Weldon, a biomedical researcher with her own lab at De Montfort University, UK, who conceived of the event and launched it last February. "My main aim has been to p

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom